This study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer with an EGFR mutation) whose cancer has worsened after initial targeted therapy. About 420 pa…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC